Sage Therapeutics announced top-lineresults froma Phase 2 clinical trial study of SAGE-217, the company’s orally administereddrug that is being researched as a hopeful treatment of major depressive disorder . Data from the trial showed that SAGE-217 met the study’s primary endpoint, which was to evaluate that the drug was safe and well-tolerated by patients.